Group 1 (n=15)
(inhaled tobramycin)

Group 2 (n=10)
(intravenous antibiotics)

Microbes

N of patients (%)

Microbes

N of patients (%)
Pseudomonas aeruginosa

12 (80%)

 Pseudomonas aeruginosa

7 (70%)
Acinetobacter baumanii/calcoaceticus

9 (60%)

 Acinetobacter baumanii/calcoaceticus

6 (60%)
Klebsilellapneumonia

3 (20%)

 Klebsilellapneumonia

3 (30%)
Proteusmirabilis

3 (20%)

 Proteusmirabilis

2 (10%)
StaphylococcusaureusMRSA

1 (7%)

 StaphylococcusaureusMRSA

1 (10%)
Enterococcusfaecalis

1 (7%)
Table 1: Results of the microbiological studies of BAL.